Skip to main content

Table 1 The prognostic values of immune landscape markers in EC

From: The immune landscape of esophageal cancer

BiomarkerPrognostic value
Clinical survivalTumor stageDifferentiation gradeMetastasisResponse to chemotherapyResponse to immunotherapy
MAGE-A11− [63]N/AN/A+ [63]N/AN/A
NY-ESO-1N/AN/AN/AN/AN/AVaccination:− [24]
TMBN/AN/AN/AN/AN/APD-1 inhibition: + [18]
MANAN/AN/AN/AN/AN/APD-1 inhibition: + [18]
PD-L1N/AN/AN/AN/AN/APD-1 inhibition: + [18]
PD-1N/A+ [67]N/A+ [67]N/AN/A
IDO1− [32, 70]N/AN/AN/A− [68]N/A
PD-L1 + IDO1− [68, 69]N/AN/AN/A− [69]N/A
TGF-βN/AN/AN/AN/A− [72]N/A
TGF-β + IL-10N/A+ [71]N/AN/AN/AN/A
IL-6N/AN/AN/AN/A− [50]N/A
CD80 or CD86N/A− [71, 73]− [71, 73]N/AN/AN/A
CD1a+ cellsN/AN/A− [73]N/AN/AN/A
CD8+ TILs+ [75]N/AN/A− [75]+ [75]N/A
CD8+/Foxp3+ ratio+ [29]N/AN/AN/AN/AN/A
CCL4highCCL20low+ [52]N/AN/AN/AN/AN/A
M2-like TAMs− [48, 49]N/AN/AN/AN/AN/A
MDSCsN/A+ [50, 51]N/AN/A− [50]N/A
  1. +, positively correlated; −, negatively correlated; N/A not available
  2. EC esophageal cancer, MAGE-A11 melanoma-associated antigen A11, NY-ESO-1 New York esophageal squamous cell carcinoma 1, TMB tumor mutation burden, MANA mutation-associated neoantigen, PD-L1 programmed death-ligand 1, PD-1 programmed cell death protein 1, CTLA-4 cytotoxic T lymphocyte-associated protein 4, IDO1 indoleamine 2,3-dioxygenase 1, TGF-β transforming growth factor-β, IL-10 interleukin-10, IL-6 interleukin-6, TILs tumor-infiltrating lymphocytes, TAM tumor-associated macrophage, MDSC myeloid-derived suppressor cell